{"id":6096,"date":"2023-01-23T08:55:16","date_gmt":"2023-01-23T08:55:16","guid":{"rendered":"https:\/\/realheart.se\/mfn_news\/dr-ulf-kjellman-strengthens-realhearts-medical-advisory-board\/"},"modified":"2023-01-23T08:55:16","modified_gmt":"2023-01-23T08:55:16","slug":"dr-ulf-kjellman-strengthens-realhearts-medical-advisory-board","status":"publish","type":"mfn_news","link":"https:\/\/realheart.se\/sv\/mfn_news\/dr-ulf-kjellman-strengthens-realhearts-medical-advisory-board\/","title":{"rendered":"Dr. Ulf Kjellman Strengthens Realheart’s Medical Advisory Board"},"content":{"rendered":"
Press Release 23 January, 2023<\/p>\n

Realheart further strengthens its expertise with the appointment of Dr. Ulf Kjellman to the company's Medical Advisory Board. Dr. Kjellman has many years of experience in advanced surgical treatment of heart failure and was the surgeon who performed the first implant of an artificial heart in Scandinavia in 2008.<\/strong><\/div>\n

Ulf Kjellman has over 35 years of experience in cardiothoracic surgery. Among other things, he was deeply involved in initiating and developing the heart transplantation and mechanical circulatory support (MCS) programme at Sahlgrenska University Hospital in Gothenburg, Uppsala University Hospital, Karolinska University Hospital in Stockholm, King Faisal Specialist Hospital Riyadh Saudi Arabia, and National Guard Hospital Riyadh Saudi Arabia. In addition, he introduced HeartMate II, HeartMate 3, Centrimag, Maquet pumps, Berlin Excor, and SynCardia TAH.<\/span><\/span><\/p>\n

In addition to extensive clinical professional experience, Kjellman has authored numerous scientific articles with a focus on cardiovascular diseases. Furthermore, his experience extends to the field of MCS, both LVAD\/RVADs with single ventricle support and TAH. <\/span><\/span><\/p>\n

\u201cWe are incredibly pleased and proud that Ulf Kjellman has chosen to assist us with his valuable expertise. His experience in cardiac surgery and transplantation at several major hospitals is of great importance for our future implantations where patients will receive Realheart\u00ae TAH. Kjellman also has an enormous network of contacts among potential customers, suppliers and partners, both in Sweden, Europe and the Middle East. I am so grateful to be able to connect him even more closely to our development work," says Ina Laura Perkins, CEO of Realheart.<\/span><\/span><\/p>\n

\n

For more information please contact:<\/span><\/span><\/strong><\/span><\/p>\n

Ina Laura Perkins, CEO<\/span><\/span><\/p>\n

Phone: +46(0)70 406 49 21\u00a0<\/span><\/span><\/p>\n

E-mail: inalaura.perkins@realheart.se<\/span><\/span><\/p>\n

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se<\/a><\/p>\n<\/div>\n

\n

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart<\/em><\/span><\/span>\u00ae<\/span><\/span><\/span><\/em> TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation.\u00a0<\/em><\/span><\/span>A unique concept in the medical technology world.<\/span><\/span><\/span><\/em><\/p>\n<\/div>\n